Immuno-Engineering of Hematopoietic Stem Cells for Durable Immune Resistance to HIV: From the CCR5Δ32 Mutation to Autologous Gene Therapies Mediated by Lentiviral Vectors
| dc.contributor.author | Barack Ndenga | |
| dc.date.accessioned | 2026-01-09T23:41:19Z | |
| dc.date.issued | 2025-01-09 | |
| dc.description | Rare cases of sustained HIV remission following hematopoietic stem cell transplantation have demonstrated that durable,systemic resistance to HIV is a biological possibility. These exceptional outcomes have fundamentally reframed the cure agenda, establishing a new paradigm: the host immune system can be engineered for intrinsic resistance. This review examines the immuno-engineering of hematopoietic stem cells (HSCs) as a foundational strategy to reconstitute a permanently HIV-resistant immune system. I trace the conceptual evolution from the protective CCR5Δ32 mutation to modern autologous therapies using lentiviral vectors and genome-editing technologies. I critically analyze the biological rationale, technological platforms, clinical progress, and translational challenges of HSC-based resistance, positioning engineered immunity as the cornerstone of a durable, one-time curative intervention. | |
| dc.description.abstract | Rare cases of sustained HIV remission following hematopoietic stem cell transplantation demonstrate that durable,systemic resistance to HIV is a biological possibility. These exceptional outcomes have fundamentally reframed the cure agenda, establishing a new paradigm: the host immune system can be engineered for intrinsic resistance. This review examines the immuno-engineering of hematopoietic stem cells (HSCs) as a foundational strategy to reconstitute a permanently HIV-resistant immune system. We trace the conceptual evolution from the protective CCR5Δ32 mutation to modern autologous therapies using lentiviral vectors and genome-editing technologies. We critically analyze the biological rationale, technological platforms, clinical progress, and translational challenges of HSC-based resistance, positioning engineered immunity not as a futuristic concept, but as the cornerstone of a durable, one-time curative intervention. Keywords : HIV cure,Hematopoietic stem cells (HSCs),Gene therapy,Immuno-engineering,CCR5,Lentiviral vectors,Genome editing (CRISPR-Cas9),Autologous transplantation,Immune reconstitution,Viral entry inhibition,Berlin patient,HIV resistance,CD4+ T cells,Translational medicine,Durable remission | |
| dc.description.provenance | Submitted by Barack Ndenga (ndengabarack@gmail.com) on 2026-01-09T23:41:19Z No. of bitstreams: 2 107th .pdf: 499830 bytes, checksum: 8e5c7dcc6f4ead12e72e8a28fb4b83a9 (MD5) license_rdf: 1166 bytes, checksum: d700fae5b268849d8bbda3dffdc09cde (MD5) | en |
| dc.description.provenance | Made available in DSpace on 2026-01-09T23:41:19Z (GMT). No. of bitstreams: 2 107th .pdf: 499830 bytes, checksum: 8e5c7dcc6f4ead12e72e8a28fb4b83a9 (MD5) license_rdf: 1166 bytes, checksum: d700fae5b268849d8bbda3dffdc09cde (MD5) Previous issue date: 2025-01-09 | en |
| dc.description.sponsorship | None | |
| dc.identifier.uri | https://africarxiv.ubuntunet.net/handle/1/10710 | |
| dc.language.iso | en | |
| dc.publisher | Publisher | |
| dc.rights | Attribution-NonCommercial-ShareAlike 3.0 United States | en |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-sa/3.0/us/ | |
| dc.title | Immuno-Engineering of Hematopoietic Stem Cells for Durable Immune Resistance to HIV: From the CCR5Δ32 Mutation to Autologous Gene Therapies Mediated by Lentiviral Vectors | |
| dc.type | Article |
